The New Biotech IPO Math
Biotech IPOs are setting record valuations--the current deals average three-to-five times the previous average IPO valuations. Behind the hysteria: a new math which values biotechs not on some discount to future earnings, but on their ability to dominate new and important pharmaceutical business areas and thereby create new monopolies.
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.